{"disease":{"id":"myocardial-infarct","name":"myocardial infarct"},"drugs":{"marketed":[{"drug_id":"apixaban","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eliquis","generic_name":"apixaban","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Factor Xa inhibitor","quality_score":85,"revenue":"14443","mechanism":"Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development."},{"drug_id":"ticagrelor","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brilinta","generic_name":"ticagrelor","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor [EPC]","quality_score":10,"revenue":"1100","mechanism":null},{"drug_id":"atorvastatin","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"prasugrel","indication_name":"ST-Elevation Myocardial Infarction with PCI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effient","generic_name":"PRASUGREL","company_name":"Cosette","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor","quality_score":80,"revenue":"400","mechanism":"Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"prasugrel","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effient","generic_name":"PRASUGREL","company_name":"Cosette","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12","drug_class":"P2Y12 Platelet Inhibitor","quality_score":80,"revenue":"400","mechanism":"Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"vorapaxar","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zontivity","generic_name":"VORAPAXAR","company_name":"Key Therap","drug_phase":"marketed","molecular_target":"Proteinase-activated receptor 1","drug_class":"Protease-activated Receptor-1 Antagonist","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"eplerenone","indication_name":"Chronic Heart Failure Following Myocardial Infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inspra","generic_name":"EPLERENONE","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Aldosterone Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Inspra works by blocking the action of aldosterone, a hormone that can cause the body to retain too much salt and water."},{"drug_id":"prazosin-hcl","indication_name":"Reducing the risk of myocardial infarctions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in non-Q-wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"non-interventional-study","indication_name":"Myocardial Infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"metoprolol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"metoprolol","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"lisinopril","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zestril","generic_name":"lisinopril","company_name":"Generic (originally Merck/AstraZeneca)","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, lowering blood pressure and reducing cardiac workload."},{"drug_id":"simvastatin","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"telmisartan","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"telmisartan","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"tirofiban","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aggrastat","generic_name":"TIROFIBAN","company_name":"Medicure","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor","quality_score":75,"revenue":null,"mechanism":"Aggrastat works by blocking the integrin alpha-IIb/beta-3 receptor on platelets, preventing them from aggregating and forming blood clots."},{"drug_id":"heparin-sodium","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"brilinta","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brilinta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"myoinositol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"warfarin","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"acetylsalicylic-acid","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"propranolol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rosuvastatin","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"eptifibatide","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Integrilin","generic_name":"EPTIFIBATIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots."},{"drug_id":"olmesartan","indication_name":"myocardial infarctions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"tenecteplase","indication_name":"Acute myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tnkase","generic_name":"TENECTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"fibrin","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Tenecteplase binds to fibrin and converts plasminogen to plasmin, enhancing fibrin-specific plasmin generation."},{"drug_id":"hctz","indication_name":"myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alteplase","indication_name":"Acute myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"dicoumarol","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dicuman","generic_name":"dicoumarol","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"NAD(P)H dehydrogenase [quinone] 1","drug_class":"dicoumarol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aprocitentan","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tryvio","generic_name":"APROCITENTAN","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure."},{"drug_id":"atenolol","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tenoretic 100","generic_name":"ATENOLOL","company_name":"Twi Pharms","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"beta-Adrenergic Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ramipril","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"clopidogrel","indication_name":"Acute ST segment elevation myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"clopidogrel","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"clopidogrel","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"amlodipine","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvasc","generic_name":"amlodipine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"Calcium channel blocker (dihydropyridine)","quality_score":55,"revenue":null,"mechanism":"Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand."},{"drug_id":"lovastatin","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"lovastatin","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"lovenox","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"activase","indication_name":"Acute myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Activase","company_name":"Medical College of Wisconsin","drug_phase":"discontinued","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"enoxaparin","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"integrilin","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"integrilin","company_name":"University of Cincinnati","drug_phase":"phase_1","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metalyse","indication_name":"Acute myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metalyse","company_name":"AO GENERIUM","drug_phase":"phase_3","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pritor","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pritor","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metoprolol","indication_name":"Myocardial Infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"amlodipin","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amlodipin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"inositol","indication_name":"Myocardial Reinfarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"perindopril-arginine","indication_name":"Myocardial Infarction Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aceon","generic_name":"PERINDOPRIL ARGININE","company_name":"Symplmed Pharms Llc","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"enoxaparin-sodium","indication_name":"Myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Non-Q wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."}],"pipeline":[],"offLabel":[],"totalMarketed":54,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06255418","title":"Big Data to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure","phase":"","overall_status":"COMPLETED","enrollment_count":7860560,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT06281054","title":"Acute Myocardial Infarction in Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4500000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03694392","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","phase":"","overall_status":"COMPLETED","enrollment_count":2776278,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT03939624","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","phase":"","overall_status":"COMPLETED","enrollment_count":419734,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03596502","title":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)","phase":"","overall_status":"COMPLETED","enrollment_count":402764,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03837535","title":"Myocardial Infarction in the Perioperative Setting","phase":"","overall_status":"COMPLETED","enrollment_count":400742,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04715594","title":"CONNECT DES Registrty","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT00669045","title":"An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)","phase":"","overall_status":"COMPLETED","enrollment_count":253668,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT07416617","title":"Impact of New-onset Insomnia After Coronary Revascularization for Patients With Acute Myocardial Infarction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":235342,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03749694","title":"Investigating Temporal Improvements in Survival Following ST-elevation Myocardial Infarction.","phase":"","overall_status":"COMPLETED","enrollment_count":232353,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT06887699","title":"The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value-Based Payment System","phase":"NA","overall_status":"RECRUITING","enrollment_count":212000,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT04088682","title":"Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT07198191","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07130968","title":"Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT02681848","title":"What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?","phase":"","overall_status":"UNKNOWN","enrollment_count":180000,"lead_sponsor_name":"University of Bristol","has_results":false},{"nct_id":"NCT05053828","title":"Type 2 Diabetes With Antiplatelet Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":173464,"lead_sponsor_name":"Tabula Rasa HealthCare","has_results":false},{"nct_id":"NCT07163767","title":"Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04008173","title":"The International Survey of Acute Coronary Syndromes-ARCHIVES","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT05974397","title":"Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":124018,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06241833","title":"Emulation of Randomized Clinical Trial in Cardiovascular Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":118420,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04047329","title":"Risk Factors and Impact of Anesthesia Techniques on Myocardial Infarction Following Transurethral Resection of the Prostate","phase":"","overall_status":"COMPLETED","enrollment_count":115025,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03032289","title":"Association Between Active Transport and Acute Myocardial Infarction","phase":"","overall_status":"COMPLETED","enrollment_count":100482,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT03099395","title":"Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT03823547","title":"Future Optimal Research and Care Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":99999,"lead_sponsor_name":"J.M. ten Berg","has_results":false},{"nct_id":"NCT04097912","title":"Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06252168","title":"Registry of Acute Myocardial Infarction","phase":"","overall_status":"RECRUITING","enrollment_count":97500,"lead_sponsor_name":"Tomsk National Research Medical Center of the Russian Academy of Sciences","has_results":false},{"nct_id":"NCT04545437","title":"The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06059079","title":"Using Higher Cut-off Values to Diagnose Acute Myocardial Infarction in Patients With Elevated Hs-cTnT Concentrations","phase":"","overall_status":"COMPLETED","enrollment_count":80000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06521801","title":"Cardio-Renal Registry","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05645926","title":"Association of Obesity and Cardiovascular Outcomes in Myocardial Infarction","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT05699629","title":"Prospective Coronary Heart Disease Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Shandong First Medical University","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04584645","title":"A Digital Flu Intervention for People With Cardiovascular Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":49138,"lead_sponsor_name":"Evidation Health","has_results":true},{"nct_id":"NCT01852123","title":"High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":48282,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03350568","title":"Dietary Antioxidants and Chronic Diseases-The Swedish National March Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":43880,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05118009","title":"Artificial Intelligence Based Rapid Identification of ST-elevation Myocardial Infarction Using Electrocardiogram (ARISE)","phase":"NA","overall_status":"COMPLETED","enrollment_count":43176,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT02374190","title":"Relationship Between Primary Percutaneous Coronary Intervention, Door-to-balloon Times, and Mortality for Heart Attack Patients Across England","phase":"","overall_status":"COMPLETED","enrollment_count":42677,"lead_sponsor_name":"London School of Economics and Political Science","has_results":false},{"nct_id":"NCT03382990","title":"Stent Placement and the Risk of New-onset AF in Patients With AMI","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT01218776","title":"International Survey of Acute Coronary Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":36000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT04104269","title":"Mechanical Structure Complications After Acute Myocardial Infarction","phase":"","overall_status":"UNKNOWN","enrollment_count":35621,"lead_sponsor_name":"Xiamen Cardiovascular Hospital, Xiamen University","has_results":false},{"nct_id":"NCT04199663","title":"Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction","phase":"","overall_status":"COMPLETED","enrollment_count":30191,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04050956","title":"French Cohort of Myocardial Infarction Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01372800","title":"Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT00526474","title":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26449,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05748691","title":"Switching From Cardiac Troponin I to T","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03218020","title":"Red Meat, Increased Iron Load and CVD Risk","phase":"","overall_status":"COMPLETED","enrollment_count":25540,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT06162039","title":"National Landscape of Hemorrhagic Myocardial Infarction in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":24181,"lead_sponsor_name":"Rohan Dharmakumar","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}